Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials
Science 37, a leader in enhancing patient access to clinical trials, has been awarded Frost & Sullivan's 2024 Global Company of the Year Award for Decentralized Clinical Trials. This prestigious honor recognizes Science 37's visionary innovation, market-leading performance, and unmatched customer care in the industry.
The award solidifies Science 37's growing influence in the clinical trial sector, which is increasingly turning to decentralization to overcome recruitment, enrollment, and retention challenges. Frost & Sullivan selected Science 37 after a rigorous analytical process considering multiple nominees and evaluating Best Practices criteria across two dimensions.
David Coman, CEO of Science 37, expressed deep honor in receiving this recognition, emphasizing the company's commitment to transforming the clinical trial process for the benefit of both patients and sponsors.
Science 37, leader nell'aumentare l'accesso dei pazienti alle sperimentazioni cliniche, ha ricevuto il 2024 Global Company of the Year Award di Frost & Sullivan per le Sperimentazioni Cliniche Decentralizzate. Questo prestigioso riconoscimento celebra l'innovazione visionaria, le prestazioni di mercato leader e l'assistenza clienti senza pari di Science 37 nel settore.
Il premio consolida l'influenza crescente di Science 37 nel settore delle sperimentazioni cliniche, che si sta sempre più orientando verso la decentralizzazione per affrontare le sfide relative a reclutamento, iscrizione e mantenimento. Frost & Sullivan ha selezionato Science 37 dopo un rigoroso processo analitico che ha considerato numerosi candidati e ha valutato i criteri delle Migliori Pratiche in due dimensioni.
David Coman, CEO di Science 37, ha espresso un profondo onore nel ricevere questo riconoscimento, sottolineando l'impegno dell'azienda nel trasformare il processo delle sperimentazioni cliniche a beneficio sia dei pazienti che degli sponsor.
Science 37, líder en mejorar el acceso de los pacientes a ensayos clínicos, ha sido galardonada con el 2024 Global Company of the Year Award de Frost & Sullivan por Ensayos Clínicos Descentralizados. Este prestigioso honor reconoce la innovación visionaria, el rendimiento líder en el mercado y el servicio al cliente inigualable de Science 37 en la industria.
El premio solidifica la creciente influencia de Science 37 en el sector de ensayos clínicos, que está orientándose cada vez más hacia la descentralización para superar los desafíos de reclutamiento, inscripción y retención. Frost & Sullivan seleccionó a Science 37 tras un riguroso proceso analítico que consideró múltiples nominados y evaluó los criterios de Mejores Prácticas en dos dimensiones.
David Coman, CEO de Science 37, expresó un profundo honor al recibir este reconocimiento, enfatizando el compromiso de la empresa en transformar el proceso de ensayos clínicos en beneficio tanto de los pacientes como de los patrocinadores.
Science 37는 임상 시험에 대한 환자의 접근성을 향상시키는 선두주자로, Frost & Sullivan의 2024 Global Company of the Year Award를 분산형 임상 시험 부문에서 수상했습니다. 이 권위 있는 상은 산업 내에서 Science 37의 비전 있는 혁신, 시장 선도적 성과 및 독보적인 고객 서비스를 인정하는 것입니다.
이번 수상은 임상 시험 분야에서 Science 37의 증가하는 영향력을 강화하며, 이 분야는 채용, 등록 및 유지 문제를 극복하기 위해 점점 더 분산화로 전환하고 있습니다. Frost & Sullivan은 여러 후보를 고려하고 두 가지 측면에서 모범 사례 기준을 평가하는 철저한 분석 과정을 거쳐 Science 37을 선정했습니다.
Science 37의 CEO인 David Coman은 이Recognition을 받게 되어 깊은 영광으로 생각하며, 환자와 스폰서를 모두 위해 임상 시험 과정을 혁신하겠다는 회사의 의지를 강조했습니다.
Science 37, un leader dans l'amélioration de l'accès des patients aux essais cliniques, a reçu le 2024 Global Company of the Year Award de Frost & Sullivan pour les Essais Cliniques Décentralisés. Cet honneur prestigieux reconnaît l'innovation visionnaire, la performance de leader sur le marché et le service client inégalé de Science 37 dans l'industrie.
Ce prix renforce l'influence croissante de Science 37 dans le secteur des essais cliniques, qui se tourne de plus en plus vers la décentralisation pour surmonter les défis de recrutement, d'inscription et de rétention. Frost & Sullivan a sélectionné Science 37 après un processus d'analyse rigoureux ayant considéré de multiples candidats et évalué les critères des Meilleures Pratiques sur deux dimensions.
David Coman, PDG de Science 37, a exprimé un profond honneur d'avoir reçu cette reconnaissance, mettant en avant l'engagement de l'entreprise à transformer le processus des essais cliniques au bénéfice des patients et des sponsors.
Science 37, ein führendes Unternehmen zur Verbesserung des Zugangs von Patienten zu klinischen Studien, wurde mit dem 2024 Global Company of the Year Award von Frost & Sullivan für Dezentrale Klinische Studien ausgezeichnet. Diese prestigeträchtigen Auszeichnung würdigt die visionäre Innovation, die marktführende Leistung und den unvergleichlichen Kundenservice von Science 37 in der Branche.
Der Preis festigt den wachsenden Einfluss von Science 37 im Bereich der klinischen Studien, der zunehmend auf Dezentralisierung setzt, um die Herausforderungen bei Rekrutierung, Anmeldung und Bindung zu überwinden. Frost & Sullivan wählte Science 37 nach einem strengen Analyseprozess aus, der mehrere Nominees berücksichtigte und die Best Practices-Kriterien in zwei Dimensionen bewertete.
David Coman, CEO von Science 37, äußerte sich tief geehrt über die erhaltene Anerkennung und betonte das Engagement des Unternehmens, den Prozess der klinischen Studien zum Nutzen sowohl der Patienten als auch der Sponsoren zu transformieren.
- None.
- None.
Top Honor Recognizes Science 37’s Visionary Innovation, Market-Leading Performance, and Unmatched Customer Care in the Decentralized Clinical Trials Industry
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, Science 37, a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global Company of the Year Award. Recognizing the market participant that exemplifies visionary innovation, market-leading performance, and unmatched customer care, the award solidifies Science 37’s growing influence in the clinical trial industry as it increasingly turns to decentralization to help overcome recruitment, enrollment, and retention challenges.
The internationally respected business consulting firm selected Science 37 after applying a rigorous analytical process that considered multiple nominees. A detailed evaluation of Best Practices criteria across two dimensions resulted in Science 37 earning the consultancy’s top honor in the decentralized clinical trials space. “Frost & Sullivan applauds Science 37 for its exemplary implementation of best practices driven by an excellent development strategy,” commented Valentina Barcia, Best Practices Research Analyst at Frost & Sullivan.
“We are deeply honored to receive the Frost & Sullivan’s Best Practices Award,” said David Coman, Chief Executive Officer at Science 37. “This recognition as the leader in decentralized clinical trials underscores the vision, dedication, and hard work of our entire team. We remain committed to transforming the clinical trial process to better serve patients and sponsors alike.”
To learn more about Science 37 and its award-winning approach, read the full Frost & Sullivan report.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. For more information, visit www.frost.com
About Science 37
Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com.
To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.
Media Inquiries
Science 37
PR@science37.com
FAQ
What award did Science 37 (SNCE) receive in 2024?
Why was Science 37 (SNCE) chosen for the Frost & Sullivan award in 2024?
How does Science 37 (SNCE) contribute to the clinical trial industry?
Who is the CEO of Science 37 (SNCE) mentioned in the 2024 award announcement?
